Walder Wyss advises on Reata’s USD 275 million loan financing

Walder Wyss team advised the funds managed by Pharmakon Advisors, LP, in connection with the closing of the term loan financing of Reata Pharmaceuticals for up to USD 275 million. 

Reata Pharmaceuticals, is a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases. Pharmakon Advisors, LP, an investor in non-dilutive debt for the life sciences industry and the investment manager of the BioPharma Credit funds. 

Walder Wyss team advised the funds managed by Pharmakon Advisors, LP. The team was led by Tervel Stoyanov (counsel, banking & finance, pictured) and included Maurus Winzap (partner, tax) and Ursina Gremtinger (managing associate, Tax). 

Suzan Abdien Hago Taha

SHARE